Setmelanotide, sold as Imcivree, is a fully FDA approved peptide, and it treats obesity in a way nothing else does. It is a cyclic eight amino acid peptide that activates the MC4 receptor in the brain.
That receptor sits at the end of the pathway your brain uses to judge how much energy you have stored and whether you should be hungry. In a small number of people, a genetic fault breaks that pathway. The brain never receives the signal that energy stores are full, so hunger is close to constant and severe obesity begins in early childhood. This is not the ordinary difficulty most people have with weight. It is a broken circuit.
Setmelanotide restores the missing signal by activating the receptor directly. For people with those specific genetic conditions, results can be dramatic in a way general weight loss drugs are not.
The catch is that it only works if that particular pathway is the problem, which is why the approvals require genetic testing first.
For educational and research purposes only. Never use any peptide or substance based on information found here — always consult a licensed healthcare professional before making any medical or health-related decision.
No reviews yet. Be the first.
AOD9604 is a fragment of human growth hormone — specifically the last 15 amino acids at one end of the molecul…
Cagrilintide is a long acting version of amylin, a hormone your pancreas releases alongside insulin whenever y…
CJC-1295 is a synthetic version of a hormone your body already produces called GHRH — growth hormone releasing…
Setmelanotide is the clearest example in this whole field of what proper evidence looks like, and it is worth understanding for contrast with everything else.
It was approved in November 2020 for chronic weight management in people aged 6 and over with obesity due to confirmed POMC, PCSK1, or LEPR deficiency. Approval for Bardet-Biedl syndrome followed in June 2022. In March 2026 the FDA expanded it again to acquired hypothalamic obesity, a condition where the brain region controlling appetite has been damaged, often by a tumor or its treatment, in adults and children from age 4.
Each of those approvals came from trials in a precisely defined group of patients, with a mechanism understood well enough to predict who would respond. That is why the drug works so well in its intended population and would do very little in anyone else.
It is a useful contrast with the general peptide market. Setmelanotide is proof that a peptide can be a genuinely effective medicine. It is also proof of how narrow and how well characterized the benefit has to be before regulators accept it.